Baird Upgrades LivaNova(LIVN.US) to Buy Rating, Raises Target Price to $66
LivaNova: Strong Buy Rating on Robust Revenue and Earnings Growth Outlook
Barclays Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $61
LivaNova (LIVN) Gets a Hold From Barclays
Baird Maintains Neutral on LivaNova, Maintains $55 Price Target
LivaNova Analyst Ratings
Baird Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $55
LivaNova Hold Rating Justified by US VNS Reimbursement Uncertainty and Italian Legal Challenges
Baird Maintains Neutral on LivaNova, Lowers Price Target to $55
Baird Maintains LivaNova(LIVN.US) With Hold Rating, Cuts Target Price to $55
LivaNova Price Target Raised to $75.00/Share From $72.00 by Needham
LivaNova Analyst Ratings
Needham Maintains Buy on LivaNova, Raises Price Target to $75
Needham Maintains LivaNova(LIVN.US) With Buy Rating, Raises Target Price to $75
Needham Raises LivaNova's Price Target to $75 From $72, Buy Rating Maintained
Piper Sandler Maintains LivaNova(LIVN.US) With Buy Rating, Maintains Target Price $75
Piper Sandler Sticks to Their Buy Rating for LivaNova (LIVN)
LivaNova Price Target Raised to $72.00/Share From $70.00 by Stifel
LivaNova Analyst Ratings
Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW) and LivaNova (LIVN)